A next generation vaccine to prevent disease caused by Neisseria meningitidis serogroup B (MenB)

BACKGROUND: OMVax has developed a meningococcal native outer membrane vesicle (NOMV) vaccine containing overexpressed, mutant Factor H binding proteins (FHbps) from subfamilies A and B with reduced FH binding and attenuated endotoxin (NOMV-FHbp). In previous studies, NOMV presented surface antigens in a native environment that elicited high titers of serum bactericidal activity (SBA) in mice and infant macaques. However, the relatively low amounts of NOMV produced by MenB strains has limited vaccine development. METHODS: We describe here a culture medium enabling commercial scale production of NOMV. We investigated the ability of antibodies elicited in mice by NOMV-FHbp alone or in combination with a MenACWY capsular polysaccharide conjugate vaccine to elicit human complement-mediated serum bactericidal activity (SBA) against strains from each capsular group. RESULTS: In CD1 wild-type (WT) mice, anti-NOMV-FHbp antibodies showed significantly greater SBA than those elicited by marketed MenB vaccine MenB-FHbp against five out of six representative MenB strains currently causing disease. The combination NOMV-FHbp+MenACWY vaccine maintained high SBA activity against strains from the different serogroups compared to each individual vaccine. In CEACAM1/FH human transgenic mice, anti-NOMV-FHbp antibodies showed greater or comparable SBA than those elicited by MenB-4C licensed vaccine against two MenB strains expressing FHbp ID 1, an amino acid sequence identical to FHbp ID 1 in the MenB-4C vaccine. CONCLUSIONS: The results show that NOMV-FHbp alone or in combination with MenACWY vaccines has the potential to broaden protection against MenB strains that are not optimally covered by existing vaccines.

Authors

Publication Details

Journal
Vaccine
Published
2026-11-17
DOI
https://doi.org/10.1016/j.vaccine.2026.129354
Primary Topic
Bacterial Infections and Vaccines
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A next generation vaccine to prevent disease caused by Neisseria meningitidis serogroup B (MenB)

Gregory R. Moe, Gregory A. Barrett‐Wilt, Serena Giuntini, Scarlet W. Tefera et al.
1 links
Vaccine
Bacterial Infections and Vaccines
article

A next generation vaccine to prevent disease caused by Neisseria meningitidis serogroup B (MenB)

Gregory R. Moe, Gregory A. Barrett‐Wilt, Serena Giuntini, Scarlet W. Tefera, Alejandro Bolanos, Adan Ramos Rivera
article en

Abstract

BACKGROUND: OMVax has developed a meningococcal native outer membrane vesicle (NOMV) vaccine containing overexpressed, mutant Factor H binding proteins (FHbps) from subfamilies A and B with reduced FH binding and attenuated endotoxin (NOMV-FHbp). In previous studies, NOMV presented surface antigens in a native environment that elicited high titers of serum bactericidal activity (SBA) in mice and infant macaques. However, the relatively low amounts of NOMV produced by MenB strains has limited vaccine development. METHODS: We describe here a culture medium enabling commercial scale production of NOMV. We investigated the ability of antibodies elicited in mice by NOMV-FHbp alone or in combination with a MenACWY capsular polysaccharide conjugate vaccine to elicit human complement-mediated serum bactericidal activity (SBA) against strains from each capsular group. RESULTS: In CD1 wild-type (WT) mice, anti-NOMV-FHbp antibodies showed significantly greater SBA than those elicited by marketed MenB vaccine MenB-FHbp against five out of six representative MenB strains currently causing disease. The combination NOMV-FHbp+MenACWY vaccine maintained high SBA activity against strains from the different serogroups compared to each individual vaccine. In CEACAM1/FH human transgenic mice, anti-NOMV-FHbp antibodies showed greater or comparable SBA than those elicited by MenB-4C licensed vaccine against two MenB strains expressing FHbp ID 1, an amino acid sequence identical to FHbp ID 1 in the MenB-4C vaccine. CONCLUSIONS: The results show that NOMV-FHbp alone or in combination with MenACWY vaccines has the potential to broaden protection against MenB strains that are not optimally covered by existing vaccines.

VaccineVol. 96
National Institute of Allergy and Infectious Diseases
Good health and well-being
Bacterial Infections and Vaccines
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon